SGMT
Sagimet Biosciences Inc.
Key Financials
Operating Income
$-56889000
↓ 4.5%
Revenue
$2.0M
0.0%
Net Income
$-51038000
↓ 12.0%
Total Assets
$116.5M
↓ 27.3%
Shareholders' Equity
$111.4M
↓ 28.5%
EPS (Diluted)
$-1.58
↓ 9.0%
Total Liabilities
$5.7M
↑ 5.5%
Cash & Equivalents
$35.0M
↓ 53.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 5/14/2026 | View on SEC |
| 3 | 5/14/2026 | View on SEC |
| 8-K | 5/12/2026 | View on SEC |
| 10-Q | 5/12/2026 | View on SEC |
| 8-K | 4/28/2026 | View on SEC |
| 424B5 | 4/28/2026 | View on SEC |
| 8-K | 4/27/2026 | View on SEC |
| 8-K | 4/27/2026 | View on SEC |
| ARS | 4/21/2026 | View on SEC |
| DEF 14A | 4/21/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | SGMT |
| Company Name | Sagimet Biosciences Inc. |
| CIK | 1400118 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (650) 561-8600 |